The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1 ...

Monte Rosa's in-house pipeline is led by MRT-2359, a molecular glue degrader that breaks down a protein called GSPT1 and is in phase 1/2 trials as a potential treatment for lung cancer and other ...

BMPS | Complete Banca Monte dei Paschi di Siena S.p.A. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.